Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis

Overview

Journal J Am Coll Cardiol

Specialty Cardiology & Vascular Diseases

Date 2024 Jan 17

PMID 38233012

Authors

Elias Bjornson

Martin Adiels

Marja-Riitta Taskinen

Stephen Burgess

M John Chapman

Chris J Packard

Jan Boren

Affiliations

Soon will be listed here.

Abstract

Background: Lipoprotein(a) (Lp(a)) is recognized as a causal factor for coronary heart disease (CHD) but its atherogenicity relative to that of low-density lipoprotein (LDL) on a per-particle basis is indeterminate.

Objectives: The authors addressed this issue in a genetic analysis based on the fact that Lp(a) and LDL both contain 1 apolipoprotein B (apoB) per particle.

Methods: Genome-wide association studies using the UK Biobank population identified 2 clusters of single nucleotide polymorphisms: one comprising 107 variants linked to Lp(a) mass concentration, the other with 143 variants linked to LDL concentration. In these Lp(a) and LDL clusters, the relationship of genetically predicted variation in apoB with CHD risk was assessed.

Results: The Mendelian randomization-derived OR for CHD for a 50 nmol/L higher Lp(a)-apoB was 1.28 (95% CI: 1.24-1.33) compared with 1.04 (95% CI: 1.03-1.05) for the same increment in LDL-apoB. Likewise, use of polygenic scores to rank subjects according to difference in Lp(a)-apoB vs difference in LDL-apoB revealed a greater HR for CHD per 50 nmol/L apoB for the Lp(a) cluster (1.47; 95% CI: 1.36-1.58) compared with the LDL cluster (1.04; 95% CI: 1.02-1.05). From these data, we estimate that the atherogenicity of Lp(a) is approximately 6-fold (point estimate of 6.6; 95% CI: 5.1-8.8) greater than that of LDL on a per-particle basis.

Conclusions: We conclude that the atherogenicity of Lp(a) (CHD risk quotient per unit increase in particle number) is substantially greater than that of LDL. Therefore, Lp(a) represents a key target for drug-based intervention in a significant proportion of the at-risk population.

Citing Articles

A Comprehensive Review of the Genetics of Dyslipidemias and Risk of Atherosclerotic Cardiovascular Disease.

Kalwick M, Roth M Nutrients. 2025; 17(4).

PMID: 40004987 PMC: 11858766. DOI: 10.3390/nu17040659.

The Interplay Between Immunity, Inflammation and Endothelial Dysfunction.

Chee Y, Dalan R, Cheung C Int J Mol Sci. 2025; 26(4).

PMID: 40004172 PMC: 11855323. DOI: 10.3390/ijms26041708.

Synergistic effects of lipoprotein (a) and fibrinogen on carotid plaque in patients with coronary artery disease.

Wei M, Liu Z, Wei M, Liu S, Jin M, Zhou Y Eur J Med Res. 2025; 30(1):129.

PMID: 39994827 PMC: 11849282. DOI: 10.1186/s40001-025-02351-7.

Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease.

Doherty S, Hernandez S, Rikhi R, Mirzai S, De Los Reyes C, McIntosh S Curr Cardiovasc Risk Rep. 2025; 19(1):8.

PMID: 39980866 PMC: 11836235. DOI: 10.1007/s12170-025-00760-1.

Coronary Artery Calcium Scoring in the Context of Widespread Lipoprotein(a) Testing: Clinical Considerations and Implications for Lipid-Lowering Therapies.

Palanisamy S, Burka S, Blaha M Curr Cardiol Rep. 2025; 27(1):52.

PMID: 39932648 DOI: 10.1007/s11886-025-02210-1.

References

van der Valk F, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul J . Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation. 2016; 134(8):611-24. PMC: 4995139. DOI: 10.1161/CIRCULATIONAHA.116.020838. View

Harazono A, Kawasaki N, Kawanishi T, Hayakawa T . Site-specific glycosylation analysis of human apolipoprotein B100 using LC/ESI MS/MS. Glycobiology. 2004; 15(5):447-62. DOI: 10.1093/glycob/cwi033. View

Lamina C, Kronenberg F . Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis. JAMA Cardiol. 2019; 4(6):575-579. PMC: 6487909. DOI: 10.1001/jamacardio.2019.1041. View

Kaiser Y, van der Toorn J, Singh S, Zheng K, Kavousi M, Sijbrands E . Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification. Eur Heart J. 2022; 43(39):3960-3967. PMC: 9840475. DOI: 10.1093/eurheartj/ehac377. View

Madsen C, Kamstrup P, Langsted A, Varbo A, Nordestgaard B . Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study. Arterioscler Thromb Vasc Biol. 2019; 40(1):255-266. DOI: 10.1161/ATVBAHA.119.312951. View

ODonoghue M, Fazio S, Giugliano R, Stroes E, Kanevsky E, Gouni-Berthold I . Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2018; 139(12):1483-1492. DOI: 10.1161/CIRCULATIONAHA.118.037184. View

Larsson S, Gill D, Mason A, Jiang T, Back M, Butterworth A . Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease: Mendelian Randomization Investigation. Circulation. 2020; 141(22):1826-1828. PMC: 7614586. DOI: 10.1161/CIRCULATIONAHA.120.045826. View

Schunkert H, Konig I, Kathiresan S, Reilly M, Assimes T, Holm H . Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011; 43(4):333-8. PMC: 3119261. DOI: 10.1038/ng.784. View

Nurmohamed N, Moriarty P, Stroes E . Considerations for routinely testing for high Lp(a). Curr Opin Lipidol. 2022; 33(3):213-218. DOI: 10.1097/MOL.0000000000000828. View

10.

Tsimikas S, Marcovina S . Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week. J Am Coll Cardiol. 2022; 80(9):934-946. DOI: 10.1016/j.jacc.2022.06.019. View

11.

Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J . UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015; 12(3):e1001779. PMC: 4380465. DOI: 10.1371/journal.pmed.1001779. View

12.

Marcovina S, Albers J, Gabel B, Koschinsky M, Gaur V . Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995; 41(2):246-55. View

13.

Baigent C, Blackwell L, Emberson J, Holland L, Reith C, Bhala N . Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753):1670-81. PMC: 2988224. DOI: 10.1016/S0140-6736(10)61350-5. View

14.

van Zuydam N, Stiby A, Abdalla M, Austin E, Dahlstrom E, McLachlan S . Genome-Wide Association Study of Peripheral Artery Disease. Circ Genom Precis Med. 2021; 14(5):e002862. PMC: 8542067. DOI: 10.1161/CIRCGEN.119.002862. View

15.

Arsenault B, Boekholdt S, Dube M, Rheaume E, Wareham N, Khaw K . Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet. 2014; 7(3):304-10. DOI: 10.1161/CIRCGENETICS.113.000400. View

16.

Burgess S, Foley C, Allara E, Staley J, Howson J . A robust and efficient method for Mendelian randomization with hundreds of genetic variants. Nat Commun. 2020; 11(1):376. PMC: 6969055. DOI: 10.1038/s41467-019-14156-4. View

17.

Pan Y, Li H, Wang Y, Meng X, Wang Y . Causal Effect of Lp(a) [Lipoprotein(a)] Level on Ischemic Stroke and Alzheimer Disease: A Mendelian Randomization Study. Stroke. 2019; 50(12):3532-3539. DOI: 10.1161/STROKEAHA.119.026872. View

18.

Nordestgaard B, Chapman M, Ray K, Boren J, Andreotti F, Watts G . Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31(23):2844-53. PMC: 3295201. DOI: 10.1093/eurheartj/ehq386. View

19.

Kronenberg F . Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill?. Atherosclerosis. 2022; 349:123-135. DOI: 10.1016/j.atherosclerosis.2022.04.008. View

20.

Nurmohamed N, Kraaijenhof J, Stroes E . Lp(a): a New Pathway to Target?. Curr Atheroscler Rep. 2022; 24(11):831-838. PMC: 9534805. DOI: 10.1007/s11883-022-01060-4. View